Modalis Therapeutics Corporation (4883.T)
JPY 78.0
(0.0%)
JPY 78.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.39 Billion JPY | 11.5% |
| 2022 | -2.7 Billion JPY | -265.75% |
| 2021 | -738.95 Million JPY | -64.8% |
| 2020 | -448.4 Million JPY | -420.29% |
| 2019 | 140 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -457.93 Million JPY | 43.47% |
| 2024 Q2 | -323.01 Million JPY | 29.46% |
| 2023 Q1 | -532.37 Million JPY | 61.78% |
| 2023 Q4 | -810.01 Million JPY | -47.66% |
| 2023 Q3 | -548.58 Million JPY | -9.53% |
| 2023 FY | -2.39 Billion JPY | 11.5% |
| 2023 Q2 | -500.85 Million JPY | 5.92% |
| 2022 Q3 | -534.13 Million JPY | 0.0% |
| 2022 FY | -2.7 Billion JPY | -265.75% |
| 2022 Q4 | -1.39 Billion JPY | -160.77% |
| 2021 FY | -738.95 Million JPY | -64.8% |
| 2020 FY | -448.4 Million JPY | -420.29% |
| 2019 FY | 140 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 174.628% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 101.66% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 99.241% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 101.476% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | 2295.157% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 109.252% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 129.805% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 105.64% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | 443.159% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 117.122% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 152.602% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 273.698% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | -1228.789% |
| Tsumura & Co. | 16.7 Billion JPY | 114.316% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 121.432% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 158.068% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 114.789% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 169.631% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 130.937% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 144.942% |
| Taiko Pharmaceutical Co.,Ltd. | -4.89 Billion JPY | 51.127% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 172.589% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | -21.857% |
| MedRx Co., Ltd | -932 Million JPY | -156.633% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 163.372% |
| Solasia Pharma K.K. | -1.11 Billion JPY | -115.092% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 131.701% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 117.465% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | -305.936% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 111.579% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 181.179% |